Fair Allocation of Scarce CAR T-Cell Therapies for Relapsed/Refractory Multiple Myeloma.
作者信息
Derman Benjamin A, Parker William F
机构信息
Section of Hematology/Oncology, University of Chicago, Chicago, Illinois.
Division of the Biological Sciences, University of Chicago, Chicago, Illinois.
出版信息
JAMA. 2023 Jul 31. doi: 10.1001/jama.2023.11846.
Abstract
摘要
相似文献
1
Fair Allocation of Scarce CAR T-Cell Therapies for Relapsed/Refractory Multiple Myeloma.复发/难治性多发性骨髓瘤稀缺嵌合抗原受体T细胞疗法的公平分配
JAMA. 2023 Jul 31. doi: 10.1001/jama.2023.11846.
2
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.复发或难治性多发性骨髓瘤患者中人性化抗CD19和抗BCMA嵌合抗原受体T细胞的联合应用：一项单臂2期试验
Lancet Haematol. 2019 Oct;6(10):e521-e529. doi: 10.1016/S2352-3026(19)30115-2. Epub 2019 Aug 1.
3
CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey.复发或难治性多发性骨髓瘤的嵌合抗原受体T细胞（CAR-T）疗法及在土耳其的可及性
Front Med (Lausanne). 2024 Aug 28;11:1413825. doi: 10.3389/fmed.2024.1413825. eCollection 2024.
4
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.复发或难治性多发性骨髓瘤患者中的GPRC5D嵌合抗原受体T细胞（OriCAR-017）（北极星研究）：一项首次人体、单中心、单臂1期试验。
Lancet Haematol. 2023 Feb;10(2):e107-e116. doi: 10.1016/S2352-3026(22)00372-6.
5
Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.伊达基奥仑赛（ide-cel）嵌合抗原受体 T 细胞疗法治疗复发/难治性多发性骨髓瘤。
Future Oncol. 2022 Jan;18(3):277-289. doi: 10.2217/fon-2021-1090. Epub 2021 Dec 2.
6
Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma.临床医生和管理人员对复发或难治性多发性骨髓瘤患者门诊应用 cilta-cabtagene autoleucel 的看法。
Front Immunol. 2024 Jun 10;15:1405452. doi: 10.3389/fimmu.2024.1405452. eCollection 2024.
7
ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell Therapy.ASTCT 实践指南委员会关于嵌合抗原受体 T 细胞治疗失败后复发/难治性多发性骨髓瘤的评估和管理的调查。
Transplant Cell Ther. 2024 Aug;30(8):750-759. doi: 10.1016/j.jtct.2024.04.007. Epub 2024 Apr 12.
8
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need.嵌合抗原受体 T 细胞疗法在复发/难治性大细胞淋巴瘤和多发性骨髓瘤中的失败：一个亟待满足的未满足需求。
Blood Rev. 2023 Jul;60:101095. doi: 10.1016/j.blre.2023.101095. Epub 2023 Apr 29.
9
BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma.BCMA CAR-T 疗法联合泊马度胺是治疗复发/难治性多发性骨髓瘤的一种安全有效的方法。
J Transl Med. 2024 Nov 29;22(1):1087. doi: 10.1186/s12967-024-05772-w.
10
Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.BCMA 靶向 CAR-T 免疫疗法治疗多发性骨髓瘤和复发性/难治性多发性骨髓瘤概述。
Scand J Immunol. 2020 Aug;92(2):e12910. doi: 10.1111/sji.12910. Epub 2020 Jun 17.
引用本文的文献
1
Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma.骨髓瘤CAR T细胞治疗中的脑静脉时间、静脉静脉时间及治疗结果
Blood Cancer J. 2025 Mar 28;15(1):47. doi: 10.1038/s41408-025-01262-4.
2
Rapid high-dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma.快速大剂量环磷酰胺作为多发性骨髓瘤晚期治疗的桥接治疗
EJHaem. 2024 Oct 20;5(6):1260-1264. doi: 10.1002/jha2.1039. eCollection 2024 Dec.
3
CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review.嵌合抗原受体T细胞及癌症T细胞疗法：转化科学综述
JAMA. 2024 Dec 10;332(22):1924-1935. doi: 10.1001/jama.2024.19462.
4
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision.癌症免疫治疗的挑战与机遇：癌症免疫治疗学会（SITC）的战略愿景。
J Immunother Cancer. 2024 Jun 19;12(6):e009063. doi: 10.1136/jitc-2024-009063.
5
Maybe you can't drive this CAR?也许你不会开这辆车？
Blood Adv. 2024 Feb 27;8(4):1030-1031. doi: 10.1182/bloodadvances.2023012244.
6
Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma.嵌合抗原受体 T 细胞在多发性骨髓瘤治疗中的应用。
Hematol Oncol Clin North Am. 2024 Apr;38(2):383-406. doi: 10.1016/j.hoc.2023.12.004. Epub 2023 Dec 28.
本文引用的文献
1
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.西达基奥仑赛或标准护理用于来那度胺难治性多发性骨髓瘤。
N Engl J Med. 2023 Jul 27;389(4):335-347. doi: 10.1056/NEJMoa2303379. Epub 2023 Jun 5.
2
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.伊达赛利珠单抗或标准方案治疗复发/难治性多发性骨髓瘤。
N Engl J Med. 2023 Mar 16;388(11):1002-1014. doi: 10.1056/NEJMoa2213614. Epub 2023 Feb 10.
3
Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience.多发性骨髓瘤 BCMA 嵌合抗原受体 T 细胞分配的伦理挑战：多机构经验。
Transplant Cell Ther. 2023 Apr;29(4):255-258. doi: 10.1016/j.jtct.2023.01.012. Epub 2023 Jan 18.
4
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.伊达比星脂质体阿仑单抗治疗复发/难治性多发性骨髓瘤：多发性骨髓瘤嵌合抗原受体 T 细胞联盟的真实世界经验。
J Clin Oncol. 2023 Apr 10;41(11):2087-2097. doi: 10.1200/JCO.22.01365. Epub 2023 Jan 9.
5
Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials.多发性骨髓瘤美国食品和药物管理局药物批准试验中的种族和民族差异分析。
Blood Adv. 2022 Mar 22;6(6):1684-1691. doi: 10.1182/bloodadvances.2021005482.
6
A Proposed Lottery System to Allocate Scarce COVID-19 Medications: Promoting Fairness and Generating Knowledge.一种提议的用于分配稀缺新冠病毒治疗药物的抽签系统：促进公平与积累知识
JAMA. 2020 Jul 28;324(4):329-330. doi: 10.1001/jama.2020.11464.
7
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.对 CD38 靶向单克隆抗体治疗耐药的多发性骨髓瘤患者的结局。
Leukemia. 2019 Sep;33(9):2266-2275. doi: 10.1038/s41375-019-0435-7. Epub 2019 Mar 11.
8
New Kidney Allocation System Associated With Increased Rates Of Transplants Among Black And Hispanic Patients.新的肾脏分配系统与黑人和西班牙裔患者移植率的提高有关。
Health Aff (Millwood). 2017 Jun 1;36(6):1078-1085. doi: 10.1377/hlthaff.2016.1625.
9
Principles for allocation of scarce medical interventions.稀缺医疗干预措施的分配原则。
Lancet. 2009 Jan 31;373(9661):423-31. doi: 10.1016/S0140-6736(09)60137-9.
Zotero 插件